Baxter Hlthcare Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER HLTHCARE CORP
BAXTER HLTHCARE CORP has seventy-eight approved drugs.
There are twenty-five US patents protecting BAXTER HLTHCARE CORP drugs. There are two tentative approvals on BAXTER HLTHCARE CORP drugs.
Summary for Baxter Hlthcare Corp
| US Patents: | 25 |
| Tradenames: | 75 |
| Ingredients: | 62 |
| NDAs: | 78 |
Drugs and US Patents for Baxter Hlthcare Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | EPINEPHRINE | epinephrine | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 220626-002 | Mar 30, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Baxter Hlthcare Corp | NOURESS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 212535-001 | Dec 13, 2019 | DISCN | Yes | No | 10,493,051 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Baxter Hlthcare Corp | FLUCONAZOLE IN SODIUM CHLORIDE 0.9% | fluconazole | INJECTABLE;INJECTION | 077947-002 | May 26, 2010 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Baxter Hlthcare Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | ZOSYN IN PLASTIC CONTAINER | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 050750-003 | Feb 24, 1998 | 7,915,229 | ⤷ Start Trial |
| Baxter Hlthcare Corp | TRANSDERM SCOP | scopolamine | SYSTEM;TRANSDERMAL | 017874-001 | Approved Prior to Jan 1, 1982 | 4,262,003 | ⤷ Start Trial |
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | 5,213,804 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Baxter Hlthcare Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Finland | 3554474 | ⤷ Start Trial |
| Portugal | 3554474 | ⤷ Start Trial |
| European Patent Office | 4117625 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Baxter Hlthcare Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1304992 | 2013C/060 | Belgium | ⤷ Start Trial | PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506 |
| 1189916 | CA 2011 00005 | Denmark | ⤷ Start Trial | PRODUCT NAME: REGADENOSON OG SALTE DERAF |
| 1087960 | C300493 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
